HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosis.

Abstract
The aim of this study was to examine the relationships between N-acetyltransferase genotypes, pharmacokinetics, and tolerability of granular slow-release para-aminosalicylic acid (GSR-PAS) in tuberculosis patients. The study was a randomized, two-period, open-label, crossover design wherein each patient received 4 g GSR-PAS twice daily or 8 g once daily alternately. The PAS concentration-time profiles were modeled by a one-compartment disposition model with three transit compartments in series to describe its absorption. Patients' NAT1 and NAT2 genotypes were determined by sequencing and restriction enzyme analysis, respectively. The number of daily vomits was modeled by a Poisson probability mass function. Comparisons of other tolerability measures by regimens, gender, and genotypes were evaluated by a linear mixed-effects model. The covariate effects associated with efavirenz, gender, and NAT1*3, NAT1*14, and NAT2*5 alleles corresponded to 25, 37, -17, -48, and -27% changes, respectively, in oral clearance of PAS. The NAT1*10 allele did not influence drug clearance. The time above the MIC of 1 mg/liter was significantly different between the two regimens but not influenced by the NAT1 or NAT2 genotypes. The occurrence and intensity of intolerance differed little between regimens. Four grams of GSR-PAS twice daily but not 8 g once daily ensured concentrations exceeding the MIC (1 mg/liter) throughout the dosing interval; PAS intolerance was not related to maximum PAS concentrations over the doses studied and was not more frequent after once-daily dosing. We confirm that the slow phenotype conferred by the NAT1*14 and NAT1*3 alleles resulted in higher PAS exposure but found no evidence of increased activity of the NAT1*10 allele.
AuthorsSherwin K B Sy, Lizanne de Kock, Andreas H Diacon, Cedric J Werely, Huiming Xia, Bernd Rosenkranz, Lize van der Merwe, Peter R Donald
JournalAntimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 59 Issue 7 Pg. 4129-38 (Jul 2015) ISSN: 1098-6596 [Electronic] United States
PMID25963985 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2015, American Society for Microbiology. All Rights Reserved.
Chemical References
  • Antitubercular Agents
  • Delayed-Action Preparations
  • Isoenzymes
  • Aminosalicylic Acid
  • Acetyltransferases
  • Arylamine N-Acetyltransferase
  • N-acetyltransferase 1
  • NAT2 protein, human
Topics
  • Acetyltransferases (genetics)
  • Adolescent
  • Adult
  • Alleles
  • Aminosalicylic Acid (adverse effects, pharmacokinetics, therapeutic use)
  • Antitubercular Agents (adverse effects, pharmacokinetics, therapeutic use)
  • Arylamine N-Acetyltransferase (genetics)
  • Bacterial Load
  • Cross-Over Studies
  • Delayed-Action Preparations
  • Drug Resistance, Bacterial
  • Female
  • Genotype
  • Humans
  • Isoenzymes (genetics)
  • Male
  • Microbial Sensitivity Tests
  • Poisson Distribution
  • Sex Characteristics
  • Tuberculosis, Multidrug-Resistant (drug therapy, microbiology)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: